Kidney Transplantation Clinical Trial
Official title:
EFFECTS OF A DIET RICH IN N-3 POLYUNSATURATED FATTY ACIDS ON SYSTEMIC INFLAMMATION IN RENAL TRANSPLANT RECIPIENTS
n-3 Polyunsaturated fatty acids (PUFAs) supplementation reduces systemic inflammation and improves renal and cardiovascular prognosis in kidney transplant recipients. A good patient compliance is often difficult to obtain because bad tasting fish oils are used as n-3 PUFA source. Therefore, we explored whether n-3 beneficial effects can be obtained by administering a diet based on n-3 rich foods.
An emerging concept in clinical nutrition is that dietary interventions may improve the
course of systemic inflammatory disorders like rheumatoid arthritis and psoriasis. Most of
this effect depends on the ability of polyunsaturated fatty acids (PUFAs) to modulate immune
and inflammatory responses. Two main families of PUFAs exist in human tissues: n-3 PUFAs
that have a marked anti-inflammatory activity and n-6 PUFAs that, conversely, promote
inflammation. Multiple mechanisms account for the modulation of the inflammatory response by
PUFAs. Recent lipidemic studies have added new mediators like lipoxins to the list of PUFA
metabolites controlling inflammation that classically included only pro-inflammatory or
anti-inflammatory prostaglandins like PGE2 and PGE3, respectively. The concerted activity of
these mediators may determine a decreased recruitment of inflammatory cells in target
tissues, with a lower release of pro-inflammatory cytokines like Interleukin-6 (IL-6) and
necrosis tumor factor-α (TNF), and their higher apoptosis rate.
n-3 PUFAs include α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), whereas linoleic acid (LA) and arachidonic acid (AA) are the main n-6 PUFAs. ALA
and LA are both essential fatty acids because they cannot be synthetized in the human body
and have to be assumed with the diet. They are the precursors of downstream immunomodulatory
long-chain fatty acids: LA is converted to AA that has marked a pro-inflammatory activity
and is further transformed in pro-inflammatory eicosanoids (PGE2) and leukotrienes. On the
contrary, ALA is converted to EPA and DHA, the precursors of anti-inflammatory
prostaglandins (PGE3) and inhibits the production of AA and the synthesis of thromboxane.
Importantly, the amount of ALA converted to EPA and DHA in humans is usually low which makes
also these fatty acids essential. The current western diet is poor of n-3 PUFAs and this
suggests that n-3 PUFAs-dependent endogenous anti-inflammatory mechanisms could be
potentiated by simultaneously increasing n-3 PUFA intake and lowering the n-6/n-3 ratio.
Indeed, a high n-6/n-3 ratio is associated to a worse clinical course in cardiovascular,
inflammatory and autoimmune diseases. With the rationale of increasing n-3 PUFAs intake and
of lowering the n-6/n-3 ratio, n-3 PUFAs supplementations like fish oil have been given with
favorable clinical results to patients affected by different chronic inflammatory diseases
including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Fish oil,
however, has a low palatability and this may cause a low patients' compliance during
prolonged therapy. Since seafood, and several fruits and vegetables have a high content of
n-3 PUFAs, dietary regimens based on these specific foods are expected to increase n-3 PUFAs
intake., thus representing an attractive alternative to the administration of exogenous fish
oils products in therapeutic programs aimed to exploit the beneficial n-3 PUFAs effects in
systemic inflammatory disorders.
Therefore, the investigators explored the effect of a diet based on food with a high n-3 and
low n-6 PUFAs content in long-term kidney transplant recipients. These patients could
benefit from an increase in n-3 PUFAs intake because a persistent systemic inflammatory
status occurs after kidney transplantation, that greatly contributes to the development of
cardiovascular diseases and of chronic allograft dysfunction. Previous studies showed that
dietary administration of n-3 increases graft survival in different animal models of organ
transplantation, whereas n-6 PUFAs had opposite effects. Recently, the efficacy of n-3 PUFAs
supplementation with canola oil in decreasing systemic inflammation and in lowering the
incidence of rejections was demonstrated also in humans.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Completed |
NCT01672957 -
ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil)
|
N/A |